title: Kisameet Clay Exhibits Potent Antibacterial Activity against the ESKAPE Pathogens.
abstract: The ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens cause an increasing number of nosocomial infections worldwide since they escape the inhibitory effect of the available antibiotics and the immune response. Here, we report the broad-spectrum and potent antibacterial activity of Kisameet clay, a natural clay mineral from British Columbia, Canada, against a group of multidrug-resistant ESKAPE strains. The results suggest that this natural clay might be developed as a therapeutic option for the treatment of serious infections caused by these important pathogens.
  
  
  OBJECTIVE
  More than 50 years of misuse and overuse of antibiotics has led to a plague of antibiotic resistance that threatens to reduce the efficacy of antimicrobial agents available for the treatment of infections due to resistant organisms. The main threat is nosocomial infections in which certain pathogens, notably the ESKAPE organisms, are essentially untreatable and contribute to increasing mortality and morbidity in surgical wards. The pipeline of novel antimicrobials in the pharmaceutical industry is essentially empty. Thus, there is a great need to seek for new sources for the treatment of recalcitrant infectious diseases. We describe experiments that demonstrate the efficacy of a "natural" medicine, Kisameet clay, against all of the ESKAPE strains. We suggest that this material is worthy of clinical investigation for the treatment of infections due to multidrug-resistant organisms.
authors.affiliation: Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.
authors.forename: Shekooh
authors.initials: S
authors.lastname: Behroozian
authors.affiliation: Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Svensson
authors.affiliation: Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada jed@mail.ubc.ca.
authors.forename: Julian
authors.initials: J
authors.lastname: Davies
mesh_terms: D000538:Aluminum Silicates / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001955:British Columbia; D000077215:Clay; D015169:Colony Count, Microbial; D003428:Cross Infection / Q000382:microbiology; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects
chemical_list: D000538:Aluminum Silicates; D000900:Anti-Bacterial Agents; D000077215:Clay
references.citation: Lett Appl Microbiol. 2011 Apr;52(4):427-9
references.pmid: 21392044
references.citation: J Antimicrob Chemother. 2009 Sep;64(3):441-6
references.pmid: 19608582
references.citation: Antimicrob Agents Chemother. 1993 Oct;37(10):2119-25
references.pmid: 8257133
references.citation: J Antimicrob Chemother. 2008 Feb;61(2):353-61
references.pmid: 18070832
references.citation: Bull Vanc Med Assoc. 1946 Jul;22:230-7
references.pmid: 20995142
references.citation: Environ Sci Technol. 2011 Apr 15;45(8):3768-73
references.pmid: 21413758
references.citation: Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308
references.pmid: 23458769
references.citation: MBio. 2015;6(4):e01129
references.pmid: 26265721
references.citation: Clin Infect Dis. 2009 Jan 1;48(1):1-12
references.pmid: 19035777
references.citation: J Infect Dis. 2008 Apr 15;197(8):1079-81
references.pmid: 18419525
references.citation: Can J Microbiol. 2007 Jul;53(7):925-9
references.pmid: 17898848
references.citation: Clays Clay Miner. 2008 Aug;56(4):437-452
references.pmid: 19079803